Details
Stereochemistry | ACHIRAL |
Molecular Formula | C7H13BrN2O2 |
Molecular Weight | 237.094 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(Br)(CC)C(=O)NC(N)=O
InChI
InChIKey=OPNPQXLQERQBBV-UHFFFAOYSA-N
InChI=1S/C7H13BrN2O2/c1-3-7(8,4-2)5(11)10-6(9)12/h3-4H2,1-2H3,(H3,9,10,11,12)
Molecular Formula | C7H13BrN2O2 |
Molecular Weight | 237.094 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Carbromal is containing bromide mild hypnotic that has been used to mild insomnia treatment. Carbromal is one of a number of hypnotics containing bromide, which releases the bromide ion on hydrolysis in the body. It has no advantages over other hypnotics. Chronic administration can cause accumulation of bromide ions which have the same distribution as chloride ions but are not actively transported out of cells and are excreted in the urine with a half-life of 10-12 days. Bromism may result from chronic carbromal ingestion and with a plasma bromine concentration of 10-15 mM, the signs are acne, cerebral retardation, cerebellar dysfunction, hyperreflexia, extensor plantar responses, and gastro¬intestinal symptoms. The risk of bromism developing makes carbromal a more dangerous drug than most other hypnotics.
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20 μM |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
BROMOETHYLBUTYRAMIDE serum | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
30 μM |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
CARBROMAL serum | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
780 mg 1 times / day multiple, oral Recommended Dose: 780 mg, 1 times / day Route: oral Route: multiple Dose: 780 mg, 1 times / day Co-administed with:: bromvaletone(65-260 mg; 1/day) Sources: |
unhealthy, 27-53 n = 6 Health Status: unhealthy Condition: sleep problems Age Group: 27-53 Sex: M+F Population Size: 6 Sources: |
Disc. AE: Drug eruption... AEs leading to discontinuation/dose reduction: Drug eruption (6%) Sources: |
5850 mg 1 times / day multiple, oral Dose: 5850 mg, 1 times / day Route: oral Route: multiple Dose: 5850 mg, 1 times / day Co-administed with:: bromvaletone(1950 mg; 1/day) Sources: |
unhealthy, 54 n = 1 Health Status: unhealthy Condition: sleep problems Age Group: 54 Sex: F Population Size: 1 Sources: |
Other AEs: Addiction... |
260 mg 1 times / day multiple, oral Recommended Dose: 260 mg, 1 times / day Route: oral Route: multiple Dose: 260 mg, 1 times / day Co-administed with:: pentobarbital sodium(97 mg; 1/day) Sources: |
unhealthy, 60-65 n = 3 Health Status: unhealthy Condition: sleep problems Age Group: 60-65 Sex: M Population Size: 3 Sources: |
Other AEs: Drug eruption... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Drug eruption | 6% Disc. AE |
780 mg 1 times / day multiple, oral Recommended Dose: 780 mg, 1 times / day Route: oral Route: multiple Dose: 780 mg, 1 times / day Co-administed with:: bromvaletone(65-260 mg; 1/day) Sources: |
unhealthy, 27-53 n = 6 Health Status: unhealthy Condition: sleep problems Age Group: 27-53 Sex: M+F Population Size: 6 Sources: |
Addiction | 1% | 5850 mg 1 times / day multiple, oral Dose: 5850 mg, 1 times / day Route: oral Route: multiple Dose: 5850 mg, 1 times / day Co-administed with:: bromvaletone(1950 mg; 1/day) Sources: |
unhealthy, 54 n = 1 Health Status: unhealthy Condition: sleep problems Age Group: 54 Sex: F Population Size: 1 Sources: |
Drug eruption | 1% | 260 mg 1 times / day multiple, oral Recommended Dose: 260 mg, 1 times / day Route: oral Route: multiple Dose: 260 mg, 1 times / day Co-administed with:: pentobarbital sodium(97 mg; 1/day) Sources: |
unhealthy, 60-65 n = 3 Health Status: unhealthy Condition: sleep problems Age Group: 60-65 Sex: M Population Size: 3 Sources: |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 14:59:36 GMT 2023
by
admin
on
Fri Dec 15 14:59:36 GMT 2023
|
Record UNII |
0Y299JY9V3
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N05CM04
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
||
|
NCI_THESAURUS |
C29756
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
||
|
WHO-VATC |
QN05CM04
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
49191
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
PRIMARY | |||
|
0Y299JY9V3
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
PRIMARY | |||
|
53
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
PRIMARY | |||
|
504
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
PRIMARY | |||
|
2067
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB06617MIG
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
PRIMARY | |||
|
m1055
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000084568
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
PRIMARY | |||
|
DTXSID8020252
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
PRIMARY | |||
|
77-65-6
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
PRIMARY | |||
|
6488
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
PRIMARY | |||
|
4100
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
PRIMARY | |||
|
201-046-6
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
PRIMARY | |||
|
CHEMBL1697828
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
PRIMARY | |||
|
C76936
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
PRIMARY | |||
|
C084812
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
PRIMARY | |||
|
DB13817
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
PRIMARY | |||
|
CARBROMAL
Created by
admin on Fri Dec 15 14:59:36 GMT 2023 , Edited by admin on Fri Dec 15 14:59:36 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |